Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2018

01-04-2018 | Research Article

miR-33a inhibits cell proliferation and invasion by targeting CAND1 in lung cancer

Authors: M. Kang, Y. Li, Y. Zhao, S. He, J. Shi

Published in: Clinical and Translational Oncology | Issue 4/2018

Login to get access

Abstract

Background

Lung cancer continues to be one of the top five causes of cancer-related mortality. This study aims to identify down- and upregulated miRNAs and mRNA which can be used as potential biomarkers and/or therapeutic targets for lung cancer.

Methods

Integrated analysis of differential expression profiles of miRNA and mRNA in lung cancer was performed by searching Gene Expression Omnibus datasets. Based on miRNA expression profiles, direct mRNA targets of miRNAs with experimental support were identified through miRTarBase. The levels of representative miRNAs and mRNAs were confirmed through qualitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR).

Results

The miR-33a was decreased in non-small cell lung cancer (NSCLC) tissues compared with the para-carcinoma tissues, whereas its target mRNA of cullin-associated NEDD8-dissociated protein 1 (CAND1) was increased in NSCLC tissues. Further research has shown that miR-33a can inhibit lung cancer cell proliferation, cell cycle progression, and migration by targeting CAND1. Moreover, the CAND1 knockout lung cancer cells showed similar results as cells transfected with miR-33a mimic.

Conclusions

These results suggested that the data mining based on online databases was an effective method in finding novel target in cancer research, and the miR-33a and CAND1 played an important role in lung cancer proliferation and cell migration.
Literature
1.
Esposito L, Conti D, Ailavajhala R, Khalil N, Giordano A. Lung cancer: are we up to the challenge? Curr Genom. 2010;11(7):513.CrossRef
2.
Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol. 2005;32(3):169.CrossRefPubMed
3.
Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ, Liu WC. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung cancer. 2013;79(2):173.CrossRefPubMed
4.
Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci. 2004;95(3):197.CrossRefPubMed
5.
Cui M, Augert A, Rongione M, Conkrite K, Parazzoli S, Nikitin AY, et al. PTEN is a potent suppressor of small cell lung cancer. Mol Cancer Res. 2014;12(5):654.CrossRefPubMedPubMedCentral
6.
7.
Tutar Y, Ozgur A, Tutar E, Tutar L, Pulliero A, Izzotti A. Regulation of oncogenic genes by MicroRNAs and pseudogenes in human lung cancer. Biomed Pharmacother = Biomedecine & pharmacotherapie. 2016;83:1182.CrossRef
8.
Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung cancer. 2013;81(3):388.CrossRefPubMed
9.
Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013;22(6):540.CrossRefPubMed
10.
Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS One. 2016;11(4):e0153046.CrossRefPubMedPubMedCentral
11.
Li G, Li M, Hu J, Lei R, Xiong H, Ji H, et al. The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis. Oncogene. 2016;36(7):989–98.CrossRefPubMed
12.
Chiu KL, Kuo TT, Kuok QY, Lin YS, Hua CH, Lin CY, et al. ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis. Sci Rep. 2015;5:16426.CrossRefPubMedPubMedCentral
13.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402.CrossRefPubMed
14.
Xiao H, Zeng J, Li H, Chen K, Yu G, Hu J, et al. MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. Oncotarget. 2015;6(15):13201.CrossRefPubMedPubMedCentral
15.
Green CM, Erdjument-Bromage H, Tempst P, Lowndes NF. A novel Rad24 checkpoint protein complex closely related to replication factor C. Curr Biol. 2000;10(1):39.CrossRefPubMed
16.
Banerjee J, Pradhan R, Gupta A, Kumar R, Sahu V, Upadhyay AD, et al. CDK4 in lung, and head and neck cancers in old age: evaluation as a biomarker. Clin Trans Oncol. 2017;19(5):571–8.CrossRef
17.
Kim H, Shin EA, Kim CG, Lee DY, Kim B, Baek NI, et al. Obovatol induces apoptosis in non-small cell lung cancer cells via C/EBP homologous protein activation. Phytother Res. 2016;30(11):1841.CrossRefPubMed
18.
Zhang L, Li L, Wei H, Guo L, Ai C, Xu H, et al. Transcriptional factor FOXO3 negatively regulates the expression of nm23-H1 in non-small cell lung cancer. Thoracic Cancer. 2016;7(1):9.CrossRefPubMed
19.
Han SY, Han HB, Tian XY, Sun H, Xue D, Zhao C, et al. MicroRNA-33a-3p suppresses cell migration and invasion by directly targeting PBX3 in human hepatocellular carcinoma. Oncotarget. 2016;7(27):42461.CrossRefPubMedPubMedCentral
20.
21.
VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Can Res. 2015;21(13):2905.CrossRef
22.
Pore MM, Hiltermann TJ, Kruyt FA. Targeting apoptosis pathways in lung cancer. Cancer Lett. 2013;332(2):359.CrossRefPubMed
23.
Korzeniewski N, Hohenfellner M, Duensing S. CAND1 promotes PLK4-mediated centriole overduplication and is frequently disrupted in prostate cancer. Neoplasia. 2012;14(9):799.CrossRefPubMedPubMedCentral
24.
25.
Zhang M, Gong W, Zuo B, Chu B, Tang Z, Zhang Y, et al. The microRNA miR-33a suppresses IL-6-induced tumor progression by binding Twist in gallbladder cancer. Oncotarget. 2016;7(48):78640.PubMedPubMedCentral
26.
Guo XF, Wang AY, Liu J. HIFs-MiR-33a-Twsit1 axis can regulate invasiveness of hepatocellular cancer cells. Eur Rev Med Pharmacol Sci. 2016;20(14):3011.PubMed
27.
Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011;4(6):575.PubMedPubMedCentral
28.
Abd-El-Fattah AA, Sadik NA, Shaker OG, Aboulftouh ML. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys. 2013;67(3):875.CrossRefPubMed
29.
Dubiel D, Gierisch ME, Huang X, Dubiel W, Naumann M. CAND1-dependent control of cullin 1-RING Ub ligases is essential for adipogenesis. Biochem Biophys Acta. 2013;1833(5):1078.CrossRefPubMed
30.
Szabo E, Riffe ME, Steinberg SM, Birrer MJ, Linnoila RI. Altered cJUN expression: an early event in human lung carcinogenesis. Can Res. 1996;56(2):305.
Metadata
Title
miR-33a inhibits cell proliferation and invasion by targeting CAND1 in lung cancer
Authors
M. Kang
Y. Li
Y. Zhao
S. He
J. Shi
Publication date
01-04-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 4/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1730-2

Other articles of this Issue 4/2018

Clinical and Translational Oncology 4/2018 Go to the issue

Research Article

Prediction of neoadjuvant chemotherapy response using diffuse optical spectroscopy in breast cancer

Research Article

Treatment of childhood astrocytomas with irinotecan and cisplatin

Special Article

Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH

Research Article

NFBD1/MDC1 participates in the regulation of proliferation and apoptosis in human laryngeal squamous cell carcinoma

Research Article

Analysis of blood markers for early breast cancer diagnosis

Research Article

Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits